imatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 1423 152459-95-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • imatinib
  • gleevec
  • imatinib mesylate
  • imatinib mesilate
  • CGP-57-148B
  • CGP57148B
  • CGP-57148
  • CGP57148
  • STI-571
  • STI571
A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.
  • Molecular weight: 493.62
  • Formula: C29H31N7O
  • CLOGP: 4.38
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 86.28
  • ALOGS: -4.53
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.05 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 20.26 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 98 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 22 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.584 High 0.90
caco2-efflux Caco-2 efflux ratio (BA/AB) 6.950 High 0.90
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 9.419 10^-6 cm/s High 0.90
dh-clint Dog hepatocyte intrinsic clearance 6.683 uL/min/10^6 cells High 0.90
dppb Dog plasma protein binding (% unbound) 17.410 % High 0.90
fcs-ppb Fetal calf serum protein binding (% unbound) 32.620 % High 0.90
herg hERG pIC50 5.322 pIC50 High 0.90
hh-clint Human hepatocyte intrinsic clearance 3.221 uL/min/10^6 cells High 0.90
hlm-clint Human liver microsomal intrinsic clearance 31.550 uL/min/mg protein High 0.90
hppb Human plasma protein binding (% unbound) 7.940 % High 0.90
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 19.409 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 17.620 High 0.90
mh-clint Mouse hepatocyte intrinsic clearance 29.444 High 0.90
mppb Mouse plasma protein binding (% unbound) 8.550 High 0.90
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 37.584 High 0.90
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
pppb Pig plasma protein binding (% unbound) 20.750 % High 0.90
rat-kpuu-brain Rat brain Kpuu 0.024 % High 1
rh-clint Rat hepatocyte intrinsic clearance 12.417 uL/min/10^6 cells High 0.90
rh-fuinc Rat hepatocyte fraction unbound in incubation 46.150 % High 0.90
rppb Rat plasma protein binding (% unbound) 9.480 % High 0.90
solubility-dd Solubility at pH 7.4 in DMSO 590.201 uM High 0.90

Approvals:

DateAgencyCompanyOrphan
Nov. 7, 2001 EMA Novartis Europharm Limited
May 10, 2001 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 2368.15 14.07 1951 46803 454600 90125093
Drug resistance 957.36 14.07 419 48335 30030 90549663
Blast crisis in myelogenous leukaemia 904.25 14.07 174 48580 487 90579206
Cytogenetic analysis abnormal 796.14 14.07 168 48586 842 90578851
Malignant neoplasm progression 687.05 14.07 521 48233 106349 90473344
Philadelphia chromosome positive 488.28 14.07 99 48655 391 90579302
Second primary malignancy 472.04 14.07 186 48568 10192 90569501
Periorbital oedema 437.13 14.07 157 48597 6642 90573051
Pleural effusion 342.94 14.07 359 48395 111632 90468061
Chronic myeloid leukaemia recurrent 324.67 14.07 65 48689 237 90579456
Gene mutation identification test positive 309.75 14.07 56 48698 96 90579597
Oncologic complication 273.70 14.07 54 48700 179 90579514
Acute lymphocytic leukaemia recurrent 237.61 14.07 79 48675 2642 90577051
Neoplasm malignant 230.30 14.07 171 48583 33709 90545984
Chronic myeloid leukaemia transformation 217.09 14.07 41 48713 100 90579593
Eyelid oedema 215.47 14.07 111 48643 11423 90568270
Haematotoxicity 215.21 14.07 114 48640 12421 90567272
Anaemia 211.51 14.07 536 48218 352266 90227427
Leukaemia recurrent 205.03 14.07 61 48693 1406 90578287
Disease progression 202.68 14.07 328 48426 156287 90423406
Chromosome analysis abnormal 190.83 14.07 37 48717 109 90579584
Muscle spasms 186.94 14.07 416 48338 251467 90328226
Arthropathy 170.45 14.07 6 48748 366236 90213457
Nausea 166.09 14.07 1091 47663 1109225 89470468
Pancytopenia 165.35 14.07 259 48495 120004 90459689
Systemic lupus erythematosus 164.77 14.07 7 48747 361889 90217804
Gastric antral vascular ectasia 163.10 14.07 45 48709 784 90578909
Bone marrow failure 161.64 14.07 136 48618 32085 90547608
Rheumatoid arthritis 155.71 14.07 10 48744 362604 90217089
Face oedema 154.68 14.07 116 48638 23202 90556491
Eye swelling 151.48 14.07 126 48628 29260 90550433
Chronic myeloid leukaemia 143.44 14.07 54 48700 2610 90577083
Fluid retention 132.74 14.07 198 48556 87893 90491800
Glossodynia 132.06 14.07 11 48743 321768 90257925
Generalised oedema 131.33 14.07 97 48657 18956 90560737
Product substitution issue 129.37 14.07 94 48660 17914 90561779
Thrombocytopenia 120.58 14.07 313 48441 208412 90371281
Oedema peripheral 114.92 14.07 352 48402 257563 90322130
Wound 114.85 14.07 14 48740 302966 90276727
Drug hypersensitivity 114.71 14.07 53 48701 463556 90116137
Conjunctival haemorrhage 112.81 14.07 51 48703 3933 90575760
Splenomegaly 110.38 14.07 75 48679 12849 90566844
Drug intolerance 109.05 14.07 503 48251 447088 90132605
Oedema 107.21 14.07 292 48462 200003 90379690
Pericardial effusion 107.14 14.07 115 48639 36718 90542975
Pericarditis 106.12 14.07 11 48743 270140 90309553
Metastases to liver 105.78 14.07 102 48652 28705 90550988
Thrombocytosis 104.39 14.07 58 48696 6943 90572750
Discomfort 103.18 14.07 13 48741 274322 90305371
Blast cell crisis 101.43 14.07 20 48734 66 90579627
Gene mutation 99.73 14.07 39 48715 2091 90577602
Lower respiratory tract infection 98.99 14.07 10 48744 250649 90329044
Joint swelling 98.59 14.07 76 48678 503224 90076469
Helicobacter infection 98.10 14.07 6 48748 226844 90352849
Therapeutic product effect decreased 97.77 14.07 16 48738 277555 90302138
Pseudoporphyria 97.69 14.07 24 48730 258 90579435
Graft versus host disease 96.23 14.07 58 48696 8086 90571607
Oral pigmentation 96.03 14.07 17 48737 24 90579669
Psoriatic arthropathy 95.92 14.07 7 48747 228328 90351365
Diarrhoea 94.47 14.07 842 47912 938348 89641345
Neutropenia 93.75 14.07 300 48454 224604 90355089
Haemoglobin decreased 93.62 14.07 243 48511 161713 90417980
Gastrointestinal stromal tumour 93.13 14.07 33 48721 1340 90578353
Bone pain 92.89 14.07 139 48615 61844 90517849
Cytopenia 92.38 14.07 76 48678 17373 90562320
Off label use 92.22 14.07 296 48458 1101956 89477737
Hepatotoxicity 91.48 14.07 118 48636 45724 90533969
Neoplasm progression 91.11 14.07 116 48638 44370 90535323
Cytogenetic abnormality 90.31 14.07 26 48728 532 90579161
Pain 90.15 14.07 258 48496 996083 89583610
Folliculitis 89.59 14.07 5 48749 204348 90375345
Fibromyalgia 87.57 14.07 6 48748 206263 90373430
Sinusitis 86.73 14.07 38 48716 343050 90236643
Swelling face 86.18 14.07 156 48598 81196 90498497
Confusional state 85.38 14.07 51 48703 386154 90193539
Leukocytosis 85.32 14.07 94 48660 30896 90548797
Type 2 diabetes mellitus 83.20 14.07 7 48747 203237 90376456
Myalgia 82.64 14.07 244 48510 174881 90404812
Recurrent cancer 80.98 14.07 35 48719 2424 90577269
Injury 77.58 14.07 8 48746 197341 90382352
Polymerase chain reaction positive 77.07 14.07 18 48736 153 90579540
Musculoskeletal stiffness 76.28 14.07 32 48722 296500 90283193
Nasopharyngitis 75.29 14.07 65 48689 407039 90172654
Irritable bowel syndrome 75.22 14.07 11 48743 207437 90372256
Impaired healing 75.06 14.07 17 48737 234182 90345511
Growth retardation 74.25 14.07 30 48724 1753 90577940
Gastrointestinal toxicity 73.93 14.07 52 48702 9415 90570278
Injection site pain 73.88 14.07 5 48749 173694 90405999
Product use issue 73.71 14.07 43 48711 329876 90249817
Chylothorax 73.02 14.07 21 48733 428 90579265
Chronic graft versus host disease 72.05 14.07 38 48716 4101 90575592
Platelet count decreased 70.58 14.07 197 48557 136772 90442921
Condition aggravated 69.93 14.07 134 48620 595411 89984282
Therapeutic response decreased 69.59 14.07 151 48603 89578 90490115
Mobility decreased 69.58 14.07 24 48730 250710 90328983
Platelet count increased 69.41 14.07 70 48684 20789 90558904
Asthma 69.26 14.07 22 48732 242138 90337555
White blood cell count increased 68.76 14.07 127 48627 67114 90512579
Vomiting 68.74 14.07 686 48068 787607 89792086
Myelofibrosis 67.45 14.07 27 48727 1540 90578153
Neoplasm recurrence 65.62 14.07 33 48721 3226 90576467
Leukaemia 65.39 14.07 38 48716 4954 90574739
Hypersensitivity 64.86 14.07 90 48664 454587 90125106
Wheezing 64.00 14.07 24 48730 238056 90341637
Intentional product use issue 63.29 14.07 19 48735 216873 90362820
Exposure via father 62.45 14.07 17 48737 281 90579412
Blood cholesterol increased 61.10 14.07 18 48736 207994 90371699
Metastases to peritoneum 60.80 14.07 34 48720 4121 90575572
Hepatic enzyme increased 60.36 14.07 63 48691 360673 90219020
Therapy non-responder 58.41 14.07 184 48570 136520 90443173
Jaundice 57.64 14.07 79 48675 32438 90547255
Completed suicide 56.70 14.07 6 48748 145052 90434641
Psoriasis 55.53 14.07 7 48747 147747 90431946
Pneumatosis intestinalis 55.45 14.07 30 48724 3407 90576286
Urticaria 55.32 14.07 52 48702 312682 90267011
Sleep disorder 54.85 14.07 19 48735 198011 90381682
Peripheral arterial occlusive disease 54.83 14.07 33 48721 4588 90575105
Exposure via body fluid 54.01 14.07 18 48736 606 90579087
Osteoarthritis 53.84 14.07 19 48735 195711 90383982
Eye haemorrhage 53.18 14.07 44 48710 10136 90569557
Cardiac output decreased 52.47 14.07 20 48734 1000 90578693
Leukopenia 52.01 14.07 145 48609 100565 90479128
Ascites 51.12 14.07 92 48662 47648 90532045
Rash 49.97 14.07 650 48104 795450 89784243
Normal newborn 49.55 14.07 62 48692 23300 90556393
Eye oedema 49.05 14.07 23 48731 1929 90577764
Breast cancer 48.15 14.07 96 48658 53665 90526028
Skin fragility 47.22 14.07 18 48736 900 90578793
Tumour excision 47.21 14.07 15 48739 433 90579260
Toxic skin eruption 47.19 14.07 50 48704 15724 90563969
Carotid intima-media thickness increased 46.94 14.07 11 48743 95 90579598
White blood cell count decreased 46.79 14.07 196 48558 166913 90412780
Left ventricular dysfunction 46.57 14.07 48 48706 14621 90565072
Blood lactate dehydrogenase increased 45.96 14.07 63 48691 25869 90553824
Bone marrow oedema 45.50 14.07 20 48734 1443 90578250
Cardiotoxicity 44.99 14.07 42 48712 11347 90568346
Tumour haemorrhage 44.51 14.07 22 48732 2072 90577621
Transdifferentiation of neoplasm 44.51 14.07 8 48746 13 90579680
Loss of personal independence in daily activities 43.35 14.07 10 48744 136095 90443598
Ill-defined disorder 42.84 14.07 23 48731 184868 90394825
Acute graft versus host disease 42.62 14.07 30 48724 5438 90574255
Right ventricular failure 42.38 14.07 52 48702 19153 90560540
Hypertension 42.29 14.07 117 48637 457415 90122278
Abortion spontaneous 41.93 14.07 91 48663 53965 90525728
Injection site erythema 41.40 14.07 3 48751 98499 90481194
Joint range of motion decreased 41.20 14.07 11 48743 135632 90444061
Skin toxicity 41.16 14.07 32 48722 6747 90572946
Aplasia 41.00 14.07 26 48728 3965 90575728
Blast cells present 40.24 14.07 14 48740 538 90579155
Wound infection 40.08 14.07 5 48749 106397 90473296
Erythrocyanosis 39.17 14.07 6 48748 0 90579693
Liver injury 38.39 14.07 22 48732 170545 90409148
Pulse waveform abnormal 38.18 14.07 9 48745 80 90579613
Ankle brachial index decreased 38.08 14.07 9 48745 81 90579612
Lip dry 37.41 14.07 5 48749 100950 90478743
Chloroma 37.16 14.07 11 48743 249 90579444
Blast cell count increased 36.97 14.07 13 48741 516 90579177
Delirium 36.75 14.07 6 48748 104353 90475340
Swelling 35.93 14.07 111 48643 418947 90160746
Disease recurrence 35.85 14.07 69 48685 37584 90542109
Grip strength decreased 35.74 14.07 4 48750 92572 90487121
Arthritis 35.67 14.07 23 48731 167292 90412401
Fall 35.64 14.07 136 48618 481674 90098019
Surgery 35.31 14.07 76 48678 44811 90534882
Therapy cessation 35.07 14.07 67 48687 36294 90543399
Therapeutic response delayed 34.36 14.07 14 48740 836 90578857
Bone marrow transplant 34.20 14.07 14 48740 846 90578847
Insomnia 34.09 14.07 81 48673 333393 90246300
Knee arthroplasty 33.66 14.07 3 48751 83179 90496514
Cardiac failure 33.47 14.07 132 48622 109364 90470329
Overdose 33.19 14.07 22 48732 157687 90422006
Loss of therapeutic response 33.12 14.07 17 48737 1735 90577958
Obesity 33.11 14.07 8 48746 105499 90474194
Chronic myeloid leukaemia (in remission) 32.64 14.07 5 48749 0 90579693
Trisomy 8 32.64 14.07 5 48749 0 90579693
Chronic graft versus host disease in skin 32.36 14.07 15 48739 1225 90578468
Hypotension 31.72 14.07 81 48673 325316 90254377
Inappropriate schedule of product administration 31.43 14.07 21 48733 149912 90429781
Obliterative bronchiolitis 31.43 14.07 19 48735 2662 90577031
Jaw operation 30.67 14.07 13 48741 858 90578835
Epilepsy 30.63 14.07 4 48750 82202 90497491
Abdominal discomfort 30.21 14.07 143 48611 477185 90102508
Exposure via partner 30.05 14.07 8 48746 121 90579572
Periorbital swelling 29.89 14.07 23 48731 4775 90574918
Contusion 29.87 14.07 56 48698 251160 90328533
Heavy chain disease 29.71 14.07 5 48749 4 90579689
Adverse event 29.64 14.07 13 48741 117405 90462288
Typhoid fever 29.33 14.07 6 48748 25 90579668
Tumour lysis syndrome 29.27 14.07 33 48721 11119 90568574
Hepatitis fulminant 29.26 14.07 21 48733 3924 90575769
Disseminated intravascular coagulation 29.02 14.07 46 48708 21492 90558201
Tumour necrosis 28.93 14.07 13 48741 988 90578705
Adenovirus reactivation 28.86 14.07 9 48745 244 90579449
Lacrimation increased 28.77 14.07 52 48702 27010 90552683
Therapy partial responder 28.23 14.07 46 48708 21997 90557696
Acute lymphocytic leukaemia 27.88 14.07 18 48736 2830 90576863
Intentional overdose 27.76 14.07 8 48746 93826 90485867
Sciatica 27.60 14.07 10 48744 101372 90478321
Chronic cutaneous lupus erythematosus 27.45 14.07 12 48742 854 90578839
Blood creatine phosphokinase increased 27.22 14.07 58 48696 33965 90545728
Prescribed underdose 27.13 14.07 4 48750 75015 90504678
Hypoaesthesia 27.07 14.07 83 48671 314127 90265566
Polyneuropathy 27.02 14.07 42 48712 19299 90560394
Gastrointestinal haemorrhage 26.94 14.07 108 48646 90140 90489553
Pubertal failure 26.53 14.07 5 48749 12 90579681
Slit-lamp tests abnormal 26.11 14.07 4 48750 0 90579693
Abortion induced 25.93 14.07 32 48722 11856 90567837
Hepatic necrosis 25.93 14.07 24 48730 6414 90573279
Blood bilirubin increased 25.88 14.07 66 48688 43404 90536289
Abortion 25.74 14.07 17 48737 2778 90576915
Therapy interrupted 25.71 14.07 72 48682 50036 90529657
Hepatic failure 25.42 14.07 62 48692 39666 90540027
Urine odour abnormal 25.37 14.07 25 48729 7219 90572474
Platelet count abnormal 25.32 14.07 20 48734 4315 90575378
Dizziness 25.03 14.07 200 48554 589084 89990609
Metastasis 24.95 14.07 23 48731 6114 90573579
Peripheral swelling 24.83 14.07 126 48628 412980 90166713
Inflammation 24.77 14.07 36 48718 178556 90401137
Lichenoid keratosis 24.77 14.07 16 48738 2518 90577175
Dry mouth 24.66 14.07 38 48716 184021 90395672
Myelodysplastic syndrome 24.60 14.07 42 48712 20861 90558832
Aspartate aminotransferase increased 24.45 14.07 115 48639 102822 90476871
Eosinophilia 24.41 14.07 50 48704 28483 90551210
Papilloedema 24.21 14.07 20 48734 4595 90575098
Minimal residual disease 24.10 14.07 9 48745 425 90579268
Spondylolysis 24.10 14.07 7 48747 148 90579545
Urinary tract infection 24.07 14.07 84 48670 305548 90274145
Migraine 23.92 14.07 41 48713 190351 90389342
Anxiety 23.82 14.07 86 48668 309686 90270007
Acute leukaemia 23.76 14.07 12 48742 1184 90578509
BK polyomavirus test positive 23.71 14.07 7 48747 157 90579536
K-ras gene mutation 23.53 14.07 5 48749 26 90579667
Stomatitis 23.35 14.07 73 48681 274625 90305068
Red blood cell count decreased 23.20 14.07 66 48688 46285 90533408
Blood creatinine increased 23.16 14.07 112 48642 101274 90478419
Hepatomegaly 23.05 14.07 32 48722 13294 90566399
Live birth 22.94 14.07 7 48747 79100 90500593
Gait inability 22.90 14.07 27 48727 146429 90433264
Hepatic cytolysis 22.79 14.07 51 48703 30865 90548828
Red blood cell sedimentation rate increased 22.73 14.07 8 48746 82587 90497106
Hypercholesterolaemia 22.71 14.07 13 48741 100879 90478814
Renal failure 22.62 14.07 134 48620 130873 90448820
Pulmonary fibrosis 22.61 14.07 15 48739 107488 90472205
Paraesthesia 22.37 14.07 65 48689 250261 90329432
Stem cell transplant 22.04 14.07 14 48740 2140 90577553
Cerebral toxoplasmosis 21.94 14.07 12 48742 1393 90578300
Computerised tomogram abnormal 21.89 14.07 15 48739 2604 90577089
Drug level increased 21.83 14.07 47 48707 27715 90551978
Nail disorder 21.70 14.07 3 48751 59064 90520629
Mesenteric panniculitis 21.68 14.07 7 48747 213 90579480
Infection 21.44 14.07 111 48643 361983 90217710
Basophilia 21.40 14.07 4 48750 9 90579684
Coagulopathy 21.34 14.07 42 48712 23247 90556446
Ejection fraction decreased 21.28 14.07 45 48709 26208 90553485
Philadelphia positive chronic myeloid leukaemia 21.15 14.07 5 48749 45 90579648
Capillary leak syndrome 21.14 14.07 15 48739 2752 90576941
Neoplasm 21.11 14.07 25 48729 8878 90570815
Alopecia 21.02 14.07 168 48586 494903 90084790
Pyoderma gangrenosum 20.66 14.07 18 48736 4446 90575247
Transaminases increased 20.64 14.07 55 48699 37137 90542556
Aspiration pleural cavity 20.60 14.07 10 48744 906 90578787
Hepatocellular carcinoma 20.52 14.07 14 48740 2414 90577279
Neutrophil morphology abnormal 20.33 14.07 4 48750 13 90579680
Renal impairment 20.28 14.07 111 48643 105310 90474383
Anaphylactic reaction 20.10 14.07 11 48743 87513 90492180
Blood pressure increased 20.06 14.07 48 48706 197169 90382524
Scleroderma-like reaction 20.05 14.07 6 48748 141 90579552
Blood alkaline phosphatase increased 19.86 14.07 64 48690 48015 90531678
Night sweats 19.85 14.07 24 48730 128742 90450951
Pulmonary hypertension 19.79 14.07 59 48695 42464 90537229
Alanine aminotransferase increased 19.76 14.07 120 48634 118218 90461475
Amyotrophic lateral sclerosis 19.64 14.07 11 48743 1337 90578356
Arthralgia 19.54 14.07 298 48456 778224 89801469
Hepatic mass 19.46 14.07 13 48741 2164 90577529
Swelling of eyelid 19.43 14.07 19 48735 5435 90574258
Pancreatic toxicity 19.41 14.07 5 48749 66 90579627
Peritoneal lesion 19.30 14.07 4 48750 18 90579675
Fibrin degradation products increased 19.23 14.07 6 48748 163 90579530
Exophthalmos 19.16 14.07 12 48742 1790 90577903
Headache 19.11 14.07 338 48416 862408 89717285
Scleroderma 19.00 14.07 20 48734 6241 90573452
Intracardiac mass 18.95 14.07 5 48749 73 90579620
Exostosis 18.83 14.07 3 48751 53131 90526562
Retroplacental haematoma 18.82 14.07 6 48748 175 90579518
Gastrointestinal angiectasia 18.82 14.07 5 48749 75 90579618
Upper respiratory tract infection 18.66 14.07 25 48729 128293 90451400
Memory impairment 18.52 14.07 50 48704 197194 90382499
Skin erosion 18.47 14.07 15 48739 3367 90576326
Blood test abnormal 18.26 14.07 37 48717 20915 90558778
Pigmentation disorder 18.05 14.07 19 48735 5930 90573763
Skin mass 17.84 14.07 21 48733 7409 90572284
Dengue fever 17.77 14.07 9 48745 893 90578800
Clonal evolution 17.76 14.07 5 48749 94 90579599
Cardiac disorder 17.73 14.07 69 48685 56803 90522890
Acute myeloid leukaemia recurrent 17.71 14.07 12 48742 2045 90577648
Gastrointestinal tract irritation 17.68 14.07 8 48746 618 90579075
Joint stiffness 17.65 14.07 10 48744 78032 90501661
Medication error 17.55 14.07 12 48742 84640 90495053
Philadelphia chromosome negative 17.51 14.07 3 48751 3 90579690
Acquired gene mutation 17.45 14.07 10 48744 1269 90578424
Adenocarcinoma gastric 17.40 14.07 8 48746 641 90579052
Hallucination 17.13 14.07 7 48747 65952 90513741
Complex regional pain syndrome 17.12 14.07 13 48741 2646 90577047
Morphoea 17.10 14.07 7 48747 423 90579270
Lung infiltration 17.06 14.07 30 48724 15252 90564441
Hepatic neoplasm 16.99 14.07 12 48742 2186 90577507
Desmoid tumour 16.94 14.07 5 48749 112 90579581
Central nervous system leukaemia 16.90 14.07 6 48748 245 90579448
Atypical femur fracture 16.85 14.07 19 48735 6402 90573291
General physical health deterioration 16.73 14.07 117 48637 354998 90224695
Blood blister 16.72 14.07 12 48742 2243 90577450
Haematocrit decreased 16.67 14.07 55 48699 41777 90537916
Growth disorder 16.64 14.07 4 48750 39 90579654
Lichen planus 16.56 14.07 13 48741 2778 90576915
Sedation 16.45 14.07 3 48751 48168 90531525
Renal disorder 16.19 14.07 51 48703 37808 90541885
Drug interaction 16.12 14.07 223 48531 276230 90303463
Viral haemorrhagic cystitis 16.02 14.07 10 48744 1483 90578210
Influenza like illness 15.96 14.07 12 48742 80599 90499094
Suicidal ideation 15.94 14.07 10 48744 73845 90505848
Palatal disorder 15.88 14.07 6 48748 293 90579400
Ocular hyperaemia 15.83 14.07 47 48707 33751 90545942
Road traffic accident 15.62 14.07 21 48733 107605 90472088
Polyhydramnios 15.58 14.07 12 48742 2496 90577197
Skin hypopigmentation 15.51 14.07 9 48745 1170 90578523
Blood disorder 15.45 14.07 20 48734 7770 90571923
Myeloid maturation arrest 15.43 14.07 3 48751 9 90579684
Monocyte morphology abnormal 15.43 14.07 3 48751 9 90579684
Parosmia 15.37 14.07 19 48735 7050 90572643
Effusion 15.35 14.07 11 48743 2051 90577642
Flushing 15.29 14.07 15 48739 88476 90491217
Myocardial ischaemia 15.27 14.07 27 48727 13787 90565906
Caesarean section 15.24 14.07 32 48722 18545 90561148
Therapy responder 15.23 14.07 6 48748 328 90579365
Epstein-Barr virus infection reactivation 15.18 14.07 10 48744 1627 90578066
Liver function test increased 15.11 14.07 14 48740 84841 90494852
Hyperleukocytosis 15.03 14.07 8 48746 879 90578814
Hypoalbuminaemia 14.97 14.07 29 48725 15868 90563825
Gastric cancer 14.87 14.07 16 48738 5120 90574573
Microangiopathy 14.76 14.07 10 48744 1705 90577988
Joint dislocation 14.75 14.07 3 48751 44579 90535114
Rash maculo-papular 14.71 14.07 52 48702 40881 90538812
Concomitant disease aggravated 14.70 14.07 24 48730 11494 90568199
Colitis ulcerative 14.70 14.07 7 48747 60259 90519434
Agitation 14.60 14.07 9 48745 67089 90512604
Pulmonary interstitial emphysema syndrome 14.57 14.07 3 48751 13 90579680
Concomitant disease progression 14.57 14.07 11 48743 2221 90577472
Cystitis 14.45 14.07 9 48745 66709 90512984
Polymerase chain reaction 14.39 14.07 3 48751 14 90579679
Complications of transplant surgery 14.35 14.07 5 48749 193 90579500
Growth failure 14.35 14.07 6 48748 383 90579310
Ear infection 14.32 14.07 10 48744 69765 90509928
Pancreatic carcinoma 14.31 14.07 20 48734 8357 90571336
Sudden death 14.29 14.07 23 48731 10886 90568807
Coombs negative haemolytic anaemia 14.29 14.07 6 48748 387 90579306
Skin hyperpigmentation 14.24 14.07 18 48736 6833 90572860
Product quality issue 14.23 14.07 13 48741 79312 90500381
Somnolence 14.18 14.07 61 48693 209023 90370670
Cachexia 14.18 14.07 18 48736 6860 90572833
Depression 14.17 14.07 99 48655 300502 90279191
Vitreous adhesions 14.17 14.07 4 48750 76 90579617
Bile duct cancer 14.16 14.07 7 48747 660 90579033
Mucosal inflammation 14.14 14.07 65 48689 57560 90522133

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 2906.77 12.41 3202 49441 467983 42100709
Drug resistance 1177.22 12.41 652 51991 33596 42535096
Blast crisis in myelogenous leukaemia 839.76 12.41 189 52454 477 42568215
Malignant neoplasm progression 704.24 12.41 764 51879 107636 42461056
Second primary malignancy 628.08 12.41 283 52360 9292 42559400
Cytogenetic analysis abnormal 624.52 12.41 153 52490 622 42568070
Philadelphia chromosome positive 539.20 12.41 131 52512 510 42568182
Drug intolerance 408.92 12.41 500 52143 79924 42488768
Pleural effusion 366.93 12.41 522 52121 96644 42472048
Neoplasm malignant 347.17 12.41 260 52383 22483 42546209
Oncologic complication 271.95 12.41 71 52572 392 42568300
Acute lymphocytic leukaemia recurrent 267.36 12.41 117 52526 3574 42565118
Chronic myeloid leukaemia recurrent 233.38 12.41 56 52587 204 42568488
Gene mutation identification test positive 214.46 12.41 51 52592 177 42568515
Gene mutation 191.94 12.41 75 52568 1706 42566986
Chronic myeloid leukaemia transformation 187.52 12.41 45 52598 164 42568528
Chromosome analysis abnormal 182.58 12.41 44 52599 164 42568528
Metastases to liver 175.36 12.41 152 52491 16174 42552518
Periorbital oedema 168.87 12.41 92 52551 4565 42564127
Leukaemia recurrent 167.53 12.41 69 52574 1807 42566885
Therapeutic response decreased 159.22 12.41 212 52431 36800 42531892
Oedema 139.57 12.41 239 52404 51762 42516930
Off label use 137.91 12.41 373 52270 637962 41930730
Recurrent cancer 127.58 12.41 55 52588 1618 42567074
Gastrointestinal stromal tumour 122.90 12.41 48 52595 1090 42567602
White blood cell count increased 120.69 12.41 207 52436 44880 42523812
Eyelid oedema 119.16 12.41 79 52564 5616 42563076
Blast cell crisis 118.45 12.41 28 52615 94 42568598
Muscle spasms 112.79 12.41 295 52348 85749 42482943
Disease progression 109.67 12.41 408 52235 143248 42425444
Drug abuse 105.12 12.41 6 52637 104765 42463927
Treatment failure 104.85 12.41 236 52407 62388 42506304
Neoplasm progression 100.77 12.41 150 52493 28850 42539842
Neoplasm recurrence 99.28 12.41 54 52589 2670 42566022
Therapy non-responder 98.31 12.41 209 52434 53150 42515542
Splenomegaly 94.66 12.41 111 52532 16936 42551756
Hypotension 92.85 12.41 109 52534 257522 42311170
Overdose 91.98 12.41 11 52632 105253 42463439
Chronic graft versus host disease 89.92 12.41 68 52575 5957 42562735
Polymerase chain reaction positive 83.43 12.41 22 52621 127 42568565
Blast cells present 82.53 12.41 29 52614 484 42568208
Thrombocytopenia 79.74 12.41 453 52190 189826 42378866
Myelofibrosis 79.74 12.41 41 52602 1806 42566886
Fluid retention 77.89 12.41 140 52503 31479 42537213
Completed suicide 77.45 12.41 13 52630 96452 42472240
Bone marrow necrosis 76.40 12.41 24 52619 277 42568415
Chronic myeloid leukaemia 76.13 12.41 44 52599 2448 42566244
Gastric antral vascular ectasia 75.76 12.41 26 52617 403 42568289
Product substitution issue 75.50 12.41 81 52562 11209 42557483
Osteonecrosis of external auditory canal 73.61 12.41 17 52626 50 42568642
Face oedema 72.59 12.41 87 52556 13579 42555113
Pericardial effusion 71.32 12.41 129 52514 29146 42539546
Necrotising panniculitis 69.30 12.41 16 52627 47 42568645
Inappropriate schedule of product administration 68.55 12.41 17 52626 95885 42472807
Bradycardia 67.57 12.41 12 52631 85472 42483220
Gastrointestinal toxicity 66.32 12.41 48 52595 3931 42564761
Acquired gene mutation 65.13 12.41 34 52609 1546 42567146
Cytogenetic abnormality 62.55 12.41 28 52615 903 42567789
Blast cell count increased 62.08 12.41 30 52613 1155 42567537
Clonal evolution 61.79 12.41 17 52626 118 42568574
Graft versus host disease 61.74 12.41 78 52565 12847 42555845
Central nervous system neoplasm 61.64 12.41 16 52627 86 42568606
Bone marrow failure 60.21 12.41 129 52514 32964 42535728
Confusional state 60.21 12.41 71 52572 167526 42401166
Loss of therapeutic response 59.64 12.41 30 52613 1261 42567431
Acute kidney injury 58.78 12.41 244 52399 367093 42201599
Generalised oedema 58.61 12.41 83 52560 15253 42553439
Central nervous system leukaemia 58.60 12.41 21 52622 372 42568320
Fall 58.20 12.41 127 52516 234393 42334299
Haematotoxicity 55.20 12.41 68 52575 10917 42557775
Bone pain 54.37 12.41 102 52541 23690 42545002
Pulmonary embolism 54.29 12.41 41 52602 119571 42449121
Scleroderma 53.27 12.41 31 52612 1747 42566945
Leukocytosis 49.73 12.41 112 52531 29596 42539096
Intentional overdose 48.53 12.41 4 52639 51452 42517240
Somnolence 48.32 12.41 62 52581 141043 42427649
Pituitary apoplexy 47.89 12.41 14 52629 124 42568568
Metastases to peritoneum 46.52 12.41 32 52611 2417 42566275
Desmoid tumour 45.75 12.41 13 52630 103 42568589
Endocarditis noninfective 45.51 12.41 14 52629 150 42568542
Haemoglobin decreased 45.06 12.41 299 52344 132172 42436520
Condition aggravated 44.31 12.41 169 52474 260585 42308107
Hyperkalaemia 44.26 12.41 22 52621 80436 42488256
Chronic graft versus host disease in skin 42.89 12.41 26 52617 1580 42567112
Exposure via father 42.71 12.41 13 52630 134 42568558
Drug hypersensitivity 42.67 12.41 36 52607 99353 42469339
Surgery 42.10 12.41 77 52566 17539 42551153
Nausea 41.87 12.41 705 51938 396094 42172598
HCoV-HKU1 infection 41.34 12.41 10 52633 38 42568654
Serositis 40.74 12.41 15 52628 288 42568404
Cytopenia 39.96 12.41 75 52568 17422 42551270
Graft versus host disease in lung 39.38 12.41 19 52624 729 42567963
Tumour excision 37.97 12.41 13 52630 200 42568492
Drug clearance decreased 37.97 12.41 27 52616 2151 42566541
Typhoid fever 36.78 12.41 10 52633 66 42568626
Anxiety 36.69 12.41 56 52587 118504 42450188
Delirium 36.20 12.41 10 52633 52509 42516183
Platelet count decreased 35.81 12.41 293 52350 138288 42430404
Blood pressure increased 35.70 12.41 44 52599 101884 42466808
Tumour haemorrhage 35.32 12.41 32 52611 3606 42565086
Myalgia 35.19 12.41 221 52422 95859 42472833
Lip scab 34.37 12.41 10 52633 87 42568605
Hallucination 34.32 12.41 14 52629 57493 42511199
Lactobacillus infection 34.22 12.41 14 52629 360 42568332
Product dose omission issue 33.95 12.41 89 52554 154276 42414416
Malaria 33.83 12.41 12 52631 206 42568486
Syncope 33.69 12.41 44 52599 99362 42469330
Dizziness 33.61 12.41 176 52467 249078 42319614
Chronic obstructive pulmonary disease 33.61 12.41 18 52625 63096 42505596
Colon cancer 33.51 12.41 50 52593 9631 42559061
Wheezing 33.25 12.41 13 52630 54768 42513924
Hyperhidrosis 32.84 12.41 38 52605 90474 42478218
Tumour necrosis 32.45 12.41 22 52621 1622 42567070
Intentional product misuse 32.45 12.41 18 52625 61882 42506810
Accident 32.26 12.41 40 52603 6463 42562229
Oedema peripheral 32.14 12.41 282 52361 135794 42432898
Intentional product use issue 32.10 12.41 25 52618 71808 42496884
Gastrectomy 32.02 12.41 11 52632 171 42568521
Metabolic acidosis 31.98 12.41 12 52631 51846 42516846
Tuberculosis 31.91 12.41 50 52593 10049 42558643
Toxicity to various agents 31.91 12.41 160 52483 228976 42339716
Thrombosis 31.70 12.41 23 52620 68488 42500204
Prostate cancer 31.68 12.41 124 52519 44519 42524173
Asthma 31.42 12.41 19 52624 62295 42506397
Type III immune complex mediated reaction 31.29 12.41 15 52628 567 42568125
Tumour rupture 31.02 12.41 13 52630 356 42568336
Bone marrow oedema 30.89 12.41 17 52626 860 42567832
Janus kinase 2 mutation 30.21 12.41 7 52636 21 42568671
Pancreatic toxicity 30.08 12.41 8 52635 48 42568644
Oral pigmentation 30.04 12.41 6 52637 6 42568686
Anaemia 29.86 12.41 499 52144 279779 42288913
Transformation to acute myeloid leukaemia 29.80 12.41 18 52625 1087 42567605
Tremor 29.77 12.41 46 52597 96883 42471809
Anaphylactic reaction 29.72 12.41 8 52635 42735 42525957
Flushing 29.68 12.41 5 52638 37023 42531669
Stress 29.40 12.41 9 52634 44203 42524489
Polycythaemia vera 29.28 12.41 13 52630 411 42568281
Seizure 29.27 12.41 66 52577 120495 42448197
Pneumonia 29.06 12.41 358 52285 421791 42146901
Graft versus host disease in eye 28.75 12.41 12 52631 325 42568367
Loss of CAR T-cell persistence 28.65 12.41 7 52636 28 42568664
Suicidal ideation 28.30 12.41 12 52631 48149 42520543
Optic neuritis 28.19 12.41 30 52613 4112 42564580
Medication error 27.66 12.41 4 52639 33150 42535542
Hyponatraemia 27.63 12.41 52 52591 101410 42467282
Pulmonary aplasia 27.61 12.41 6 52637 12 42568680
Gastric cancer 27.32 12.41 38 52605 6865 42561827
Psoriasis 27.16 12.41 13 52630 48591 42520101
Eye swelling 27.10 12.41 51 52592 11869 42556823
Ascites 27.08 12.41 140 52503 56538 42512154
Agitation 26.74 12.41 24 52619 64290 42504402
Skin hypopigmentation 26.63 12.41 12 52631 393 42568299
Growth failure 26.50 12.41 8 52635 80 42568612
Pemphigus 26.36 12.41 21 52622 1985 42566707
Acoustic neuroma 26.02 12.41 9 52634 143 42568549
Rash 25.89 12.41 483 52160 276471 42292221
Metastases to gastrointestinal tract 25.81 12.41 8 52635 88 42568604
Chloroma 25.46 12.41 13 52630 564 42568128
Loss of personal independence in daily activities 25.38 12.41 15 52628 49801 42518891
Metamyelocyte count increased 24.98 12.41 12 52631 456 42568236
Stem cell transplant 24.96 12.41 23 52620 2649 42566043
Cardiac arrest 24.82 12.41 62 52581 109258 42459434
Growth retardation 24.81 12.41 22 52621 2410 42566282
Demyelination 24.80 12.41 26 52617 3503 42565189
Suicide attempt 24.76 12.41 13 52630 46087 42522605
Musculoskeletal stiffness 24.69 12.41 21 52622 57744 42510948
Renal tuberculosis 24.56 12.41 6 52637 24 42568668
Aggression 24.39 12.41 12 52631 44151 42524541
Pancytopenia 24.25 12.41 237 52406 117506 42451186
Therapeutic product effect decreased 24.24 12.41 9 52634 39141 42529551
Concomitant disease aggravated 24.21 12.41 35 52608 6551 42562141
Dehydration 23.96 12.41 92 52551 141675 42427017
Urticaria 23.84 12.41 34 52609 74002 42494690
Neuropathy peripheral 23.72 12.41 57 52586 101796 42466896
Pigmentation disorder 23.58 12.41 24 52619 3124 42565568
Inclusion body myositis 23.46 12.41 7 52636 67 42568625
Heart rate decreased 23.30 12.41 8 52635 36524 42532168
Bone neoplasm 23.29 12.41 10 52633 291 42568401
Trisomy 8 23.28 12.41 7 52636 69 42568623
Cytokine release syndrome 23.26 12.41 13 52630 44514 42524178
Epistaxis 23.23 12.41 29 52614 66797 42501895
Deep vein thrombosis 23.17 12.41 37 52606 76920 42491772
Right ventricular diastolic collapse 23.10 12.41 7 52636 71 42568621
Drug ineffective 22.89 12.41 973 51670 629224 41939468
Post embolisation syndrome 22.84 12.41 7 52636 74 42568618
C-kit gene mutation 22.79 12.41 4 52639 0 42568692
Wallerian degeneration 22.79 12.41 4 52639 0 42568692
Acute aortic syndrome 22.79 12.41 4 52639 0 42568692
Oral hyperaesthesia 22.79 12.41 4 52639 0 42568692
Spleen palpable 22.79 12.41 4 52639 0 42568692
Atrial fibrillation 22.69 12.41 92 52551 139501 42429191
Lactic acidosis 22.54 12.41 14 52629 45247 42523445
Myopathy toxic 22.41 12.41 13 52630 728 42567964
Bone marrow disorder 22.35 12.41 19 52624 1967 42566725
Glomerulonephritis 21.88 12.41 21 52622 2545 42566147
Peripheral arterial occlusive disease 21.80 12.41 34 52609 6804 42561888
Remission not achieved 21.66 12.41 8 52635 155 42568537
Myeloid leukaemia 21.55 12.41 11 52632 477 42568215
Pseudoporphyria 21.42 12.41 11 52632 483 42568209
International normalised ratio increased 21.22 12.41 17 52626 48151 42520541
Bone marrow transplant 21.10 12.41 15 52628 1194 42567498
Acute graft versus host disease 21.02 12.41 37 52606 8178 42560514
Leukaemic infiltration 21.02 12.41 8 52635 169 42568523
Mental status changes 21.01 12.41 13 52630 42102 42526590
Complications of transplant surgery 20.97 12.41 11 52632 505 42568187
Nightmare 20.91 12.41 3 52640 25009 42543683
Nail discolouration 20.90 12.41 15 52628 1212 42567480
Blindness 20.87 12.41 59 52584 17919 42550773
Axonal neuropathy 20.81 12.41 15 52628 1220 42567472
Therapy partial responder 20.66 12.41 63 52580 19958 42548734
Cytogenetic response 20.56 12.41 4 52639 3 42568689
Pericardial excision 20.56 12.41 4 52639 3 42568689
Rectosigmoid cancer 20.39 12.41 8 52635 184 42568508
B-cell small lymphocytic lymphoma 20.27 12.41 8 52635 187 42568505
Arterial disorder 20.21 12.41 15 52628 1277 42567415
Nephropathy 20.17 12.41 33 52610 6878 42561814
Myelocyte count increased 20.13 12.41 10 52633 409 42568283
Product prescribing error 19.91 12.41 4 52639 26108 42542584
Cardio-respiratory arrest 19.81 12.41 26 52617 58610 42510082
Platelet count increased 19.78 12.41 42 52601 10661 42558031
Blood lactate dehydrogenase increased 19.77 12.41 74 52569 26007 42542685
Blood pressure decreased 19.57 12.41 26 52617 58306 42510386
Constipation 19.46 12.41 119 52524 162172 42406520
Dengue fever 19.46 12.41 10 52633 440 42568252
Platelet dysfunction 19.45 12.41 9 52634 314 42568378
Retroperitoneal fibrosis 19.41 12.41 10 52633 442 42568250
Drug dependence 19.20 12.41 6 52637 29088 42539604
Disease recurrence 19.11 12.41 80 52563 29598 42539094
Hepatic calcification 18.85 12.41 9 52634 337 42568355
Diaphragmatic disorder 18.52 12.41 14 52629 1225 42567467
Chest expansion decreased 18.47 12.41 7 52636 146 42568546
Costal cartilage fracture 18.47 12.41 8 52635 238 42568454
Obstructive airways disorder 18.45 12.41 4 52639 24755 42543937
Tachycardia 18.12 12.41 64 52579 101023 42467669
Foetal exposure during pregnancy 18.10 12.41 19 52624 47292 42521400
Azoospermia 17.85 12.41 10 52633 524 42568168
Oxygen saturation decreased 17.74 12.41 33 52610 64654 42504038
Oropharyngeal pain 17.51 12.41 16 52627 42494 42526198
Large intestine infection 17.41 12.41 17 52626 2104 42566588
Orbital oedema 17.30 12.41 7 52636 175 42568517
Metastasis 17.29 12.41 25 52618 4680 42564012
Nasopharyngitis 17.28 12.41 50 52593 83946 42484746
Vomiting 17.22 12.41 474 52169 289249 42279443
Therapy cessation 17.18 12.41 60 52583 20390 42548302
Ocular myasthenia 17.13 12.41 10 52633 567 42568125
Arthritis 17.12 12.41 16 52627 42049 42526643
Hepatotoxicity 17.12 12.41 69 52574 25098 42543594
Hepatic embolisation 17.09 12.41 3 52640 0 42568692
Cytoreductive surgery 17.09 12.41 3 52640 0 42568692
Blood thrombin 17.09 12.41 3 52640 0 42568692
Philadelphia chromosome negative 17.02 12.41 4 52639 13 42568679
Intestinal congestion 17.02 12.41 4 52639 13 42568679
Biopsy bone marrow abnormal 17 12.41 8 52635 290 42568402
Back pain 16.97 12.41 104 52539 141672 42427020
Chronic myelomonocytic leukaemia 16.97 12.41 11 52632 752 42567940
Adrenomegaly 16.92 12.41 9 52634 425 42568267
Neoplasm 16.92 12.41 29 52614 6276 42562416
Ventricular fibrillation 16.92 12.41 8 52635 30115 42538577
Toxic epidermal necrolysis 16.81 12.41 6 52637 26744 42541948
Swelling face 16.76 12.41 73 52570 27481 42541211
Sleep disorder 16.58 12.41 21 52622 48074 42520618
Gelatinous transformation of the bone marrow 16.58 12.41 4 52639 15 42568677
Generalised tonic-clonic seizure 16.44 12.41 6 52637 26373 42542319
Cardiogenic shock 16.43 12.41 12 52631 35628 42533064
Acute leukaemia 16.40 12.41 13 52630 1220 42567472
Blood pressure systolic increased 16.38 12.41 7 52636 27961 42540731
Angioedema 16.32 12.41 17 52626 42460 42526232
Drug interaction 16.28 12.41 232 52411 266767 42301925
Autoimmune lymphoproliferative syndrome 16.11 12.41 7 52636 210 42568482
Incorrect route of product administration 16.06 12.41 5 52638 24300 42544392
Brown-Sequard syndrome 16.05 12.41 5 52638 56 42568636
Psychotic disorder 16.03 12.41 8 52635 29200 42539492
Presyncope 15.92 12.41 4 52639 22383 42546309
Marrow hyperplasia 15.91 12.41 13 52630 1274 42567418
Orthostatic hypotension 15.86 12.41 9 52634 30561 42538131
Vital capacity decreased 15.45 12.41 9 52634 508 42568184
Abscess drainage 15.42 12.41 8 52635 359 42568333
Therapy change 15.40 12.41 22 52621 4073 42564619
Acute lymphocytic leukaemia refractory 15.25 12.41 6 52637 139 42568553
Unresponsive to stimuli 15.24 12.41 10 52633 31393 42537299
Dysarthria 15.22 12.41 16 52627 39791 42528901
Insomnia 15.08 12.41 85 52558 118168 42450524
Lacrimation increased 15.06 12.41 40 52603 11718 42556974
Lichen sclerosus 15.04 12.41 4 52639 24 42568668
Multiple-drug resistance 15.02 12.41 30 52613 7292 42561400
Mutagenic effect 15.02 12.41 3 52640 3 42568689
Breast oedema 15.02 12.41 3 52640 3 42568689
Bence Jones proteinuria 15.02 12.41 3 52640 3 42568689
Dropped head syndrome 15.00 12.41 7 52636 249 42568443
Foetal death 14.97 12.41 7 52636 250 42568442
Rhabdomyolysis 14.93 12.41 48 52595 77971 42490721
Acute promyelocytic leukaemia 14.89 12.41 10 52633 726 42567966
Skin toxicity 14.86 12.41 28 52615 6521 42562171
Product use issue 14.84 12.41 47 52596 76704 42491988
Leukaemia 14.77 12.41 26 52617 5746 42562946
Nephrotic syndrome 14.73 12.41 33 52610 8685 42560007
Colon neoplasm 14.73 12.41 9 52634 555 42568137
Abdominal pain 14.71 12.41 323 52320 190148 42378544
Bladder neoplasm surgery 14.63 12.41 4 52639 27 42568665
Lipase increased 14.61 12.41 37 52606 10529 42558163
Urinary tract infection 14.56 12.41 68 52575 99216 42469476
Hyperleukocytosis 14.50 12.41 17 52626 2591 42566101
Metastases to heart 14.43 12.41 6 52637 161 42568531
Encephalopathy 14.30 12.41 18 52625 41315 42527377
Haemorrhagic ascites 14.29 12.41 6 52637 165 42568527
Lactose intolerance 14.14 12.41 13 52630 1493 42567199
Ventricular tachycardia 14.11 12.41 10 52633 30150 42538542
Diabetic ketoacidosis 14.08 12.41 5 52638 22362 42546330
Melanosis 14.04 12.41 4 52639 32 42568660
Polyomavirus-associated nephropathy 14.00 12.41 25 52618 5590 42563102
Aplasia 13.96 12.41 23 52620 4820 42563872
Cerebral toxoplasmosis 13.93 12.41 15 52628 2083 42566609
Migraine 13.89 12.41 7 52636 25407 42543285
Pseudomyxoma peritonei 13.81 12.41 3 52640 6 42568686
Clear cell sarcoma of soft tissue 13.81 12.41 3 52640 6 42568686
Aspiration bone marrow 13.81 12.41 3 52640 6 42568686
Therapy responder 13.68 12.41 6 52637 184 42568508
Chronic graft versus host disease in intestine 13.68 12.41 8 52635 455 42568237
Skin depigmentation 13.60 12.41 8 52635 460 42568232
Irritability 13.59 12.41 9 52634 28119 42540573
Colitis 13.45 12.41 23 52620 46549 42522143
Chronic eosinophilic leukaemia 13.34 12.41 4 52639 39 42568653
Pneumonia aspiration 13.33 12.41 26 52617 50052 42518640
Lung diffusion test decreased 13.29 12.41 10 52633 869 42567823
Oral lichen planus 13.22 12.41 6 52637 200 42568492
Metastases to bladder 13.21 12.41 5 52638 104 42568588
Bone development abnormal 13.16 12.41 4 52639 41 42568651
Rhinorrhoea 13.05 12.41 12 52631 31782 42536910
Hydrocele operation 12.95 12.41 3 52640 9 42568683
Drug-induced liver injury 12.90 12.41 17 52626 38256 42530436
Unevaluable event 12.86 12.41 14 52629 34274 42534418
Acute myeloid leukaemia 12.80 12.41 58 52585 22198 42546494
Hallucination, visual 12.73 12.41 5 52638 21015 42547677
Eye oedema 12.72 12.41 10 52633 927 42567765
Neck pain 12.71 12.41 11 52632 30003 42538689
Oesophageal papilloma 12.71 12.41 3 52640 10 42568682
Eye haemorrhage 12.68 12.41 22 52621 4808 42563884
Acinetobacter sepsis 12.66 12.41 5 52638 117 42568575
Lung neoplasm malignant 12.63 12.41 52 52591 19095 42549597
Alveolar proteinosis 12.61 12.41 9 52634 721 42567971
Mastocytosis 12.52 12.41 4 52639 49 42568643
Pulmonary hypertension 12.51 12.41 60 52583 23509 42545183
Parakeratosis 12.49 12.41 6 52637 228 42568464
Blast cell proliferation 12.49 12.41 3 52640 11 42568681

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 3220.16 12.82 3086 71795 695783 109818635
Drug resistance 1712.81 12.82 812 74069 55562 110458856
Blast crisis in myelogenous leukaemia 1138.81 12.82 235 74646 773 110513645
Malignant neoplasm progression 972.60 12.82 862 74019 173705 110340713
Cytogenetic analysis abnormal 885.68 12.82 199 74682 1070 110513348
Second primary malignancy 810.02 12.82 342 74539 17726 110496692
Philadelphia chromosome positive 732.05 12.82 160 74721 740 110513678
Pleural effusion 578.79 12.82 656 74225 177053 110337365
Periorbital oedema 460.35 12.82 194 74687 9998 110504420
Acute lymphocytic leukaemia recurrent 371.85 12.82 142 74739 5645 110508773
Chromosome analysis abnormal 354.60 12.82 72 74809 213 110514205
Gene mutation identification test positive 336.92 12.82 70 74811 240 110514178
Disease progression 320.99 12.82 585 74296 243449 110270969
Chronic myeloid leukaemia recurrent 314.10 12.82 69 74812 328 110514090
Leukaemia recurrent 283.71 12.82 99 74782 3032 110511386
Chronic myeloid leukaemia transformation 277.11 12.82 60 74821 263 110514155
Gene mutation 267.42 12.82 97 74784 3332 110511086
Neoplasm malignant 256.81 12.82 208 74673 36935 110477483
Eyelid oedema 232.71 12.82 139 74742 15123 110499295
Product substitution issue 216.50 12.82 155 74726 22906 110491512
Thrombocytopenia 216.43 12.82 621 74260 348264 110166154
Metastases to liver 185.24 12.82 169 74712 35217 110479201
Therapeutic response decreased 182.98 12.82 273 74608 96226 110418192
Chronic myeloid leukaemia 181.89 12.82 78 74803 4195 110510223
Oedema 178.72 12.82 421 74460 209555 110304863
Rheumatoid arthritis 176.01 12.82 6 74875 299607 110214811
Generalised oedema 175.29 12.82 154 74727 30550 110483868
Face oedema 173.55 12.82 159 74722 33310 110481108
Bone marrow failure 172.00 12.82 204 74677 57644 110456774
Splenomegaly 171.05 12.82 138 74743 24360 110490058
Anaemia 165.66 12.82 771 74110 546315 109968103
Cytogenetic abnormality 160.86 12.82 51 74830 1151 110513267
Muscle spasms 160.79 12.82 483 74398 277674 110236744
Pericardial effusion 155.81 12.82 193 74688 57024 110457394
Contraindicated product administered 153.21 12.82 3 74878 248264 110266154
Arthropathy 149.47 12.82 12 74869 287510 110226908
Drug hypersensitivity 146.60 12.82 62 74819 454028 110060390
Blast cell crisis 142.05 12.82 31 74850 142 110514276
Haematotoxicity 141.38 12.82 116 74765 20966 110493452
Polymerase chain reaction positive 139.29 12.82 35 74846 323 110514095
Fluid retention 139.18 12.82 238 74643 94069 110420349
Drug intolerance 138.06 12.82 593 74288 405919 110108499
Gastrointestinal stromal tumour 135.86 12.82 52 74829 2079 110512339
Recurrent cancer 134.32 12.82 59 74822 3364 110511054
Gastrointestinal toxicity 133.27 12.82 87 74794 11061 110503357
Pancytopenia 132.62 12.82 376 74505 209237 110305181
Chronic graft versus host disease 130.99 12.82 81 74800 9376 110505042
Myelofibrosis 130.87 12.82 56 74825 2995 110511423
Completed suicide 123.55 12.82 11 74870 242370 110272048
Gastric antral vascular ectasia 120.69 12.82 41 74840 1156 110513262
Psoriatic arthropathy 118.96 12.82 3 74878 196758 110317660
Leukocytosis 117.71 12.82 163 74718 53665 110460753
Graft versus host disease 116.82 12.82 99 74782 18707 110495711
Hepatotoxicity 116.79 12.82 177 74704 63223 110451195
Nausea 114.61 12.82 1308 73573 1234382 109280036
Neoplasm recurrence 113.33 12.82 60 74821 5172 110509246
Neoplasm progression 112.89 12.82 176 74705 64419 110449999
Oral pigmentation 112.85 12.82 21 74860 32 110514386
Therapeutic product effect decreased 112.20 12.82 16 74865 244300 110270118
Confusional state 110.54 12.82 93 74788 468587 110045831
Duodenal ulcer perforation 106.34 12.82 3 74878 177697 110336721
Glossodynia 105.63 12.82 13 74868 221991 110292427
Helicobacter infection 105.54 12.82 4 74877 181873 110332545
Haemoglobin decreased 103.72 12.82 387 74494 248340 110266078
White blood cell count increased 102.48 12.82 212 74669 96630 110417788
Oedema peripheral 101.35 12.82 466 74415 328194 110186224
Neutropenia 99.59 12.82 509 74372 374111 110140307
Joint swelling 99.45 12.82 92 74789 442753 110071665
Eye swelling 98.97 12.82 117 74764 32931 110481487
Therapy non-responder 98.31 12.82 281 74600 157026 110357392
Bone pain 98.23 12.82 166 74715 64967 110449451
Thrombocytosis 97.57 12.82 70 74811 10374 110504044
Wound 97.44 12.82 20 74861 234417 110280001
Pain 97.35 12.82 327 74554 954628 109559790
Asthma 96.77 12.82 25 74856 250266 110264152
Blast cells present 96.66 12.82 33 74848 945 110513473
Injection site pain 96.56 12.82 6 74875 177916 110336502
Growth retardation 96.47 12.82 43 74838 2539 110511879
Drug abuse 96.23 12.82 6 74875 177405 110337013
Pseudoporphyria 94.89 12.82 31 74850 772 110513646
Platelet count decreased 94.78 12.82 357 74524 230086 110284332
Discomfort 94.18 12.82 16 74865 214691 110299727
Wheezing 94.00 12.82 28 74853 255202 110259216
Musculoskeletal stiffness 92.19 12.82 37 74844 279785 110234633
Sinusitis 91.77 12.82 43 74838 296645 110217773
Off label use 91.25 12.82 619 74262 1499566 109014852
Bone marrow necrosis 91.03 12.82 26 74855 405 110514013
Lower respiratory tract infection 90.76 12.82 26 74855 243080 110271338
Acquired gene mutation 90.69 12.82 42 74839 2712 110511706
Folliculitis 89.96 12.82 6 74875 167647 110346771
Myalgia 89.38 12.82 342 74539 222039 110292379
Nasopharyngitis 88.44 12.82 82 74799 394279 110120139
Fall 88.17 12.82 172 74709 603310 109911108
Cytopenia 87.52 12.82 105 74776 30011 110484407
Metastases to peritoneum 85.27 12.82 51 74830 5559 110508859
Hypotension 83.93 12.82 141 74740 523708 109990710
Blast cell count increased 83.51 12.82 34 74847 1603 110512815
Impaired healing 83.38 12.82 16 74865 196701 110317717
Overdose 81.91 12.82 28 74853 233766 110280652
Pemphigus 81.86 12.82 22 74859 214548 110299870
Pericarditis 80.75 12.82 24 74857 219090 110295328
Injury 80.47 12.82 12 74869 177253 110337165
Urticaria 79.24 12.82 60 74821 318797 110195621
Sleep disorder 78.41 12.82 19 74862 198625 110315793
Chylothorax 76.54 12.82 29 74852 1127 110513291
Condition aggravated 75.91 12.82 250 74631 734586 109779832
Mobility decreased 75.62 12.82 33 74848 237389 110277029
Clonal evolution 75.45 12.82 20 74861 232 110514186
Bursitis 74.88 12.82 3 74878 129915 110384503
Diarrhoea 72.81 12.82 1128 73753 1138377 109376041
Conjunctival haemorrhage 72.60 12.82 49 74832 6584 110507834
Irritable bowel syndrome 72.54 12.82 12 74869 164203 110350215
Ascites 72.36 12.82 180 74701 92628 110421790
Chronic graft versus host disease in skin 71.17 12.82 35 74846 2584 110511834
Osteoarthritis 71.04 12.82 18 74863 182605 110331813
Central nervous system leukaemia 70.59 12.82 23 74858 568 110513850
Blood cholesterol increased 70.38 12.82 19 74862 184766 110329652
Ill-defined disorder 70.33 12.82 11 74870 156842 110357576
Hypersensitivity 70.14 12.82 103 74778 403895 110110523
Type 2 diabetes mellitus 69.85 12.82 17 74864 177215 110337203
Loss of therapeutic response 69.57 12.82 34 74847 2476 110511942
Necrotising panniculitis 69.04 12.82 15 74866 67 110514351
Product use issue 68.47 12.82 66 74815 311629 110202789
Bone marrow oedema 68.26 12.82 32 74849 2124 110512294
Inappropriate schedule of product administration 66.94 12.82 27 74854 203610 110310808
Arthritis 66.19 12.82 16 74865 167570 110346848
Therapy partial responder 66.17 12.82 102 74779 36959 110477459
Desmoid tumour 63.46 12.82 17 74864 206 110514212
Disease recurrence 63.05 12.82 132 74749 60652 110453766
Intentional overdose 62.42 12.82 8 74873 132493 110381925
Intentional product use issue 61.13 12.82 47 74834 247859 110266559
Osteonecrosis of external auditory canal 61.00 12.82 17 74864 241 110514177
Swelling face 59.69 12.82 167 74714 92154 110422264
Acute graft versus host disease 58.74 12.82 57 74824 12824 110501594
Rash 58.71 12.82 829 74052 820135 109694283
Blood lactate dehydrogenase increased 57.79 12.82 106 74775 44228 110470190
Cardiotoxicity 57.70 12.82 64 74817 16817 110497601
Delirium 57.18 12.82 11 74870 135014 110379404
Stem cell transplant 56.49 12.82 36 74845 4391 110510027
Drug clearance decreased 56.31 12.82 35 74846 4087 110510331
Tumour necrosis 55.79 12.82 29 74852 2407 110512011
Loss of personal independence in daily activities 54.24 12.82 17 74864 150003 110364415
Tumour excision 52.92 12.82 19 74862 633 110513785
Skin fragility 52.14 12.82 22 74859 1136 110513282
Peripheral arterial occlusive disease 51.87 12.82 46 74835 9234 110505184
Obesity 50.69 12.82 8 74873 113343 110401075
Bone marrow transplant 50.60 12.82 24 74857 1636 110512782
Psoriasis 50.37 12.82 16 74865 139977 110374441
Metastasis 50.28 12.82 43 74838 8224 110506194
Hypertension 50.25 12.82 177 74704 509907 110004511
Dizziness 49.57 12.82 274 74607 697919 109816499
Surgery 49.20 12.82 95 74786 41188 110473230
Hepatic enzyme increased 48.95 12.82 89 74792 320803 110193615
Anxiety 48.91 12.82 100 74781 344978 110169440
Injection site erythema 48.72 12.82 4 74877 94172 110420246
Tumour haemorrhage 48.64 12.82 35 74846 5210 110509208
Carotid intima-media thickness increased 48.43 12.82 12 74869 104 110514314
Toxic skin eruption 48.10 12.82 75 74806 27440 110486978
Treatment failure 48.06 12.82 337 74544 276897 110237521
Trisomy 8 47.87 12.82 9 74872 15 110514403
Ankle brachial index decreased 45.98 12.82 11 74870 81 110514337
Joint range of motion decreased 45.51 12.82 13 74868 121819 110392599
Endocarditis noninfective 45.24 12.82 14 74867 291 110514127
Pituitary apoplexy 44.79 12.82 14 74867 301 110514117
Chloroma 44.59 12.82 18 74863 830 110513588
Cerebral toxoplasmosis 43.74 12.82 27 74854 3115 110511303
Graft versus host disease in eye 43.43 12.82 15 74866 445 110513973
Urinary tract infection 43.37 12.82 98 74783 326184 110188234
HCoV-HKU1 infection 43.29 12.82 10 74871 62 110514356
White blood cell count decreased 42.82 12.82 284 74597 229106 110285312
Lip dry 42.70 12.82 8 74873 100075 110414343
Grip strength decreased 42.62 12.82 3 74878 80171 110434247
Central nervous system neoplasm 42.43 12.82 12 74869 180 110514238
Aplasia 41.97 12.82 38 74843 7835 110506583
Migraine 41.73 12.82 33 74848 171619 110342799
Anaphylactic reaction 41.23 12.82 13 74868 114287 110400131
Contusion 40.95 12.82 59 74822 233302 110281116
Skin toxicity 40.83 12.82 45 74836 11738 110502680
Medication error 39.80 12.82 11 74870 105355 110409063
Platelet count increased 39.54 12.82 67 74814 26267 110488151
Pancreatic toxicity 39.35 12.82 10 74871 97 110514321
Transdifferentiation of neoplasm 38.98 12.82 10 74871 101 110514317
Scleroderma 38.60 12.82 33 74848 6308 110508110
Wound infection 38.50 12.82 9 74872 96456 110417962
Blood bilirubin increased 38.35 12.82 126 74755 75846 110438572
Tumour rupture 38.15 12.82 15 74866 645 110513773
Platelet dysfunction 37.94 12.82 14 74867 505 110513913
Lactobacillus infection 37.91 12.82 14 74867 506 110513912
Pulmonary aplasia 37.79 12.82 6 74875 0 110514418
Erythrocyanosis 37.79 12.82 6 74875 0 110514418
Colon cancer 37.76 12.82 51 74830 16392 110498026
Lip scab 37.73 12.82 10 74871 116 110514302
Graft versus host disease in lung 37.50 12.82 18 74863 1260 110513158
Acute lymphocytic leukaemia 37.14 12.82 31 74850 5734 110508684
Pubertal failure 37.11 12.82 7 74874 12 110514406
Therapy cessation 37.08 12.82 89 74792 44768 110469650
Blood pressure increased 36.49 12.82 75 74806 258298 110256120
Swelling 36.46 12.82 119 74762 350922 110163496
Pulse waveform abnormal 35.82 12.82 9 74872 83 110514335
Inflammation 35.77 12.82 47 74834 193191 110321227
Exposure via father 35.63 12.82 9 74872 85 110514333
Eye oedema 35.62 12.82 22 74859 2540 110511878
Janus kinase 2 mutation 35.48 12.82 7 74874 17 110514401
Skin hypopigmentation 35.33 12.82 18 74863 1433 110512985
Paraesthesia 35.18 12.82 85 74796 276436 110237982
Suicidal ideation 35.12 12.82 10 74871 93927 110420491
Post embolisation syndrome 34.73 12.82 9 74872 95 110514323
Cardiac output decreased 34.58 12.82 20 74861 2049 110512369
Vomiting 34.48 12.82 833 74048 909842 109604576
Flushing 34.23 12.82 14 74867 104722 110409696
Bradycardia 34.05 12.82 33 74848 155484 110358934
Pneumatosis intestinalis 33.84 12.82 35 74846 8494 110505924
Dry mouth 33.68 12.82 52 74829 199896 110314522
Insomnia 33.59 12.82 128 74753 360462 110153956
Suicide attempt 33.50 12.82 14 74867 103380 110411038
Malaise 33.18 12.82 293 74588 671526 109842892
Mucosal inflammation 33.11 12.82 141 74740 96000 110418418
Lacrimation increased 33.01 12.82 68 74813 30882 110483536
Knee arthroplasty 32.93 12.82 3 74878 64945 110449473
Eosinophilia 32.83 12.82 100 74781 57836 110456582
Blood creatinine increased 32.67 12.82 224 74657 182665 110331753
Road traffic accident 32.52 12.82 16 74865 107382 110407036
Sciatica 32.46 12.82 11 74870 92388 110422030
Drug ineffective 32.08 12.82 1295 73586 1519245 108995173
Interstitial lung disease 31.98 12.82 182 74699 139152 110375266
Leukaemia 31.92 12.82 32 74849 7486 110506932
Chronic myeloid leukaemia (in remission) 31.91 12.82 6 74875 10 110514408
Amaurosis fugax 31.91 12.82 20 74861 2370 110512048
Slit-lamp tests abnormal 31.49 12.82 5 74876 0 110514418
Type III immune complex mediated reaction 31.41 12.82 15 74866 1038 110513380
Disseminated intravascular coagulation 31.04 12.82 79 74802 41207 110473211
Sedation 30.97 12.82 5 74876 69678 110444740
Therapy change 30.94 12.82 36 74845 9961 110504457
Hypoaesthesia 30.93 12.82 109 74772 314114 110200304
Eye haemorrhage 30.90 12.82 39 74842 11735 110502683
Acute myeloid leukaemia 30.84 12.82 75 74806 38035 110476383
Arterial disorder 30.71 12.82 19 74862 2200 110512218
Azoospermia 30.65 12.82 10 74871 248 110514170
Left ventricular dysfunction 30.40 12.82 56 74825 23437 110490981
Therapeutic response delayed 30.27 12.82 16 74865 1374 110513044
Epilepsy 30.23 12.82 15 74866 100194 110414224
Growth failure 30.02 12.82 10 74871 265 110514153
Gait inability 29.78 12.82 29 74852 136347 110378071
Right ventricular diastolic collapse 29.71 12.82 8 74873 99 110514319
Jaundice 29.68 12.82 98 74783 59138 110455280
Metastases to gastrointestinal tract 29.65 12.82 9 74872 175 110514243
Hyperkalaemia 29.51 12.82 29 74852 135767 110378651
Alopecia 29.32 12.82 137 74744 364616 110149802
Chronic obstructive pulmonary disease 29.12 12.82 19 74862 109139 110405279
Philadelphia chromosome negative 29.01 12.82 6 74875 20 110514398
Blindness 28.83 12.82 71 74810 36288 110478130
Papilloedema 28.67 12.82 30 74851 7379 110507039
Metabolic acidosis 28.51 12.82 16 74865 99728 110414690
Myelodysplastic syndrome 28.47 12.82 72 74809 37412 110477006
Serositis 28.46 12.82 16 74865 1553 110512865
Liver injury 28.44 12.82 36 74845 150377 110364041
Pyrexia 28.28 12.82 802 74079 897463 109616955
Prostate cancer 28.27 12.82 72 74809 37569 110476849
Jaw operation 28.19 12.82 13 74868 831 110513587
Obliterative bronchiolitis 28.19 12.82 22 74859 3701 110510717
Gastric cancer 28.15 12.82 36 74845 10972 110503446
Loss of CAR T-cell persistence 28.15 12.82 6 74875 24 110514394
Somnolence 28.08 12.82 105 74776 297344 110217074
Red blood cell sedimentation rate increased 28.07 12.82 9 74872 78293 110436125
Cytomegalovirus infection reactivation 28.00 12.82 47 74834 18286 110496132
Hallucination 27.96 12.82 17 74864 101415 110413003
Bone development abnormal 27.92 12.82 7 74874 64 110514354
Blood pressure fluctuation 27.91 12.82 8 74873 74816 110439602
Incorrect route of product administration 27.58 12.82 5 74876 64056 110450362
Cardiac tamponade 27.39 12.82 36 74845 11271 110503147
Metamyelocyte count increased 27.16 12.82 12 74869 694 110513724
Polycythaemia vera 27.11 12.82 11 74870 514 110513904
Red blood cell count decreased 26.95 12.82 102 74779 65821 110448597
Feeling hot 26.94 12.82 14 74867 91092 110423326
Lactose intolerance 26.84 12.82 19 74862 2757 110511661
Live birth 26.72 12.82 7 74874 69477 110444941
Tumour lysis syndrome 26.42 12.82 62 74819 30739 110483679
Hepatomegaly 26.40 12.82 50 74831 21364 110493054
Adverse event 26.34 12.82 21 74860 108788 110405630
Nail disorder 26.10 12.82 4 74877 57931 110456487
Lipase increased 26.06 12.82 46 74835 18626 110495792
Tremor 25.84 12.82 62 74819 202170 110312248
Leukopenia 25.84 12.82 181 74700 148610 110365808
Heavy chain disease 25.68 12.82 5 74876 11 110514407
Blood pressure systolic increased 25.68 12.82 12 74869 82979 110431439
Right ventricular failure 25.33 12.82 55 74826 25899 110488519
Lichenoid keratosis 25.26 12.82 26 74855 6276 110508142
Peripheral swelling 25.23 12.82 165 74716 403869 110110549
Acute aortic syndrome 25.19 12.82 4 74877 0 110514418
Wallerian degeneration 25.19 12.82 4 74877 0 110514418
Blood alkaline phosphatase increased 25.18 12.82 105 74776 70830 110443588
Pneumonia 25.15 12.82 430 74451 876284 109638134
Back pain 24.98 12.82 148 74733 370848 110143570
Pulmonary embolism 24.91 12.82 69 74812 214405 110300013
Lower limb fracture 24.73 12.82 10 74871 75338 110439080
Stress 24.67 12.82 21 74860 105327 110409091
Headache 24.60 12.82 435 74446 881942 109632476
Haemorrhagic ascites 24.57 12.82 9 74872 318 110514100
Depression 24.45 12.82 121 74760 317214 110197204
Pericardial excision 24.42 12.82 6 74875 50 110514368
Nail discolouration 24.36 12.82 20 74861 3615 110510803
Renal impairment 24.31 12.82 214 74667 188231 110326187
Swelling of eyelid 24.09 12.82 26 74855 6627 110507791
Intentional product misuse 23.91 12.82 33 74848 132871 110381547
Marrow hyperplasia 23.90 12.82 15 74866 1781 110512637
Memory impairment 23.90 12.82 62 74819 196882 110317536
Hyponatraemia 23.84 12.82 72 74809 217581 110296837
Neck pain 23.77 12.82 29 74852 123101 110391317
Pigmentation disorder 23.76 12.82 27 74854 7284 110507134
Nasal congestion 23.75 12.82 19 74862 98263 110416155
Cardiac failure 23.65 12.82 212 74669 187414 110327004
Parakeratosis 23.62 12.82 10 74871 521 110513897
Hepatic calcification 23.60 12.82 9 74872 356 110514062
Accidental exposure to product 23.60 12.82 3 74878 50005 110464413
Agitation 23.59 12.82 25 74856 113026 110401392
Haematocrit decreased 23.57 12.82 98 74783 66019 110448399
Hyperhidrosis 23.48 12.82 58 74823 187240 110327178
Urine odour abnormal 23.45 12.82 27 74854 7388 110507030
Lichen planus 23.36 12.82 19 74862 3391 110511027
Cancer surgery 23.32 12.82 12 74869 975 110513443
Nephrotic syndrome 23.21 12.82 37 74844 13794 110500624
Intra-abdominal haemorrhage 23.17 12.82 23 74858 5319 110509099
Skin hyperpigmentation 23.13 12.82 29 74852 8667 110505751
Orthostatic hypotension 23.07 12.82 8 74873 66241 110448177
Pulmonary hypertension 23.04 12.82 86 74795 55134 110459284
Multiple-drug resistance 23.03 12.82 36 74845 13199 110501219
General physical health deterioration 23.00 12.82 181 74700 425114 110089304
Chronic cutaneous lupus erythematosus 22.96 12.82 12 74869 1007 110513411
Oral hyperaesthesia 22.96 12.82 4 74877 3 110514415
Axonal neuropathy 22.72 12.82 16 74865 2302 110512116
Costal cartilage fracture 22.68 12.82 8 74873 253 110514165
Product quality issue 22.68 12.82 12 74869 77287 110437131
Ejection fraction decreased 22.64 12.82 70 74811 40810 110473608
Heart rate decreased 22.63 12.82 14 74867 82742 110431676
Essential thrombocythaemia 22.63 12.82 9 74872 399 110514019
Frequent bowel movements 22.59 12.82 10 74871 71380 110443038
Cytogenetic response 22.42 12.82 4 74877 4 110514414
Anaphylactic shock 22.24 12.82 4 74877 51542 110462876
Generalised tonic-clonic seizure 22.02 12.82 5 74876 54675 110459743
Back injury 21.99 12.82 3 74878 47396 110467022
Ileus paralytic 21.93 12.82 33 74848 11704 110502714
Inclusion body myositis 21.87 12.82 6 74875 80 110514338
Aspiration pleural cavity 21.85 12.82 14 74867 1723 110512695
Product dose omission issue 21.85 12.82 128 74753 321654 110192764
Therapy responder 21.74 12.82 9 74872 443 110513975
Renal tuberculosis 21.73 12.82 6 74875 82 110514336
Glomerulonephritis 21.70 12.82 21 74860 4709 110509709
Hepatosplenomegaly 21.55 12.82 25 74856 6894 110507524
COVID-19 21.53 12.82 89 74792 244971 110269447
Myeloid leukaemia 21.38 12.82 11 74870 894 110513524
Bone erosion 21.36 12.82 3 74878 46368 110468050
Viral haemorrhagic cystitis 21.33 12.82 18 74863 3381 110511037
Myelocyte count increased 21.28 12.82 11 74870 903 110513515
Polyomavirus-associated nephropathy 21.26 12.82 27 74854 8174 110506244
Nephropathy 21.20 12.82 35 74846 13432 110500986
Concomitant disease aggravated 21.16 12.82 39 74842 16325 110498093
Pseudomyxoma peritonei 21.15 12.82 4 74877 7 110514411
C-kit gene mutation 21.15 12.82 4 74877 7 110514411
Rhinorrhoea 21.09 12.82 23 74858 102643 110411775
Infection 21.07 12.82 151 74730 362049 110152369
Adrenomegaly 21.02 12.82 9 74872 482 110513936
Minimal residual disease 20.84 12.82 11 74870 942 110513476
Philadelphia positive chronic myeloid leukaemia 20.75 12.82 7 74874 193 110514225
Gastrectomy 20.67 12.82 10 74871 712 110513706
Chronic eosinophilic leukaemia 20.65 12.82 5 74876 39 110514379
Renal disorder 20.59 12.82 77 74804 49402 110465016
BK virus infection 20.55 12.82 34 74847 13072 110501346
Abdominal pain 20.50 12.82 473 74408 512516 110001902
Remission not achieved 20.41 12.82 9 74872 518 110513900
Chest expansion decreased 20.35 12.82 7 74874 205 110514213
Delayed puberty 20.35 12.82 7 74874 205 110514213
Acute graft versus host disease in intestine 20.35 12.82 22 74859 5617 110508801
Optic neuritis 20.35 12.82 31 74850 11116 110503302
Skin depigmentation 20.27 12.82 12 74869 1284 110513134
Intestinal congestion 20.19 12.82 4 74877 10 110514408
Ocular myasthenia 19.96 12.82 10 74871 768 110513650
Acute respiratory distress syndrome 19.87 12.82 80 74801 53118 110461300
Bone marrow disorder 19.84 12.82 19 74862 4204 110510214
Basophilia 19.82 12.82 5 74876 47 110514371
Normal newborn 19.80 12.82 45 74836 21851 110492567
Acute graft versus host disease in skin 19.79 12.82 30 74851 10710 110503708
Polymerase chain reaction 19.75 12.82 6 74875 117 110514301
Chronic myelomonocytic leukaemia 19.71 12.82 11 74870 1052 110513366
Musculoskeletal toxicity 19.68 12.82 7 74874 227 110514191
Spleen palpable 19.66 12.82 4 74877 12 110514406
Autoimmune lymphoproliferative syndrome 19.59 12.82 7 74874 230 110514188
Bone metabolism disorder 19.43 12.82 9 74872 581 110513837
Lung infiltration 19.43 12.82 48 74833 24580 110489838
Mesenteric panniculitis 19.29 12.82 9 74872 591 110513827
Pyoderma gangrenosum 19.13 12.82 21 74860 5455 110508963
Neoplasm 19.07 12.82 30 74851 11057 110503361
Myocardial ischaemia 18.97 12.82 50 74831 26634 110487784
Retroplacental haematoma 18.94 12.82 6 74875 135 110514283
Mucosal pigmentation 18.90 12.82 3 74878 0 110514418
Blood thrombin 18.90 12.82 3 74878 0 110514418
Metastases to heart 18.76 12.82 8 74873 424 110513994
Oxygen saturation decreased 18.61 12.82 50 74831 156932 110357486
Pulmonary haemorrhage 18.55 12.82 37 74844 16419 110497999
Diaphragmatic disorder 18.44 12.82 13 74868 1873 110512545
Alveolar proteinosis 18.39 12.82 12 74869 1524 110512894
Acute promyelocytic leukaemia 18.38 12.82 13 74868 1883 110512535
Chronic graft versus host disease in liver 18.36 12.82 10 74871 912 110513506
Demyelination 18.32 12.82 27 74854 9402 110505016
Thrombotic microangiopathy 18.12 12.82 52 74829 29097 110485321
Chronic graft versus host disease in intestine 18.09 12.82 9 74872 681 110513737
Angiocentric lymphoma 18.00 12.82 11 74870 1246 110513172
Hypercholesterolaemia 17.95 12.82 21 74860 90816 110423602
BK polyomavirus test positive 17.72 12.82 7 74874 305 110514113
Brown-Sequard syndrome 17.68 12.82 5 74876 75 110514343
Chronic lymphocytic leukaemia 17.65 12.82 21 74860 5947 110508471
Arthralgia 17.60 12.82 398 74483 779234 109735184
Adenovirus reactivation 17.50 12.82 9 74872 731 110513687
Myopathy toxic 17.47 12.82 11 74870 1314 110513104
Blood blister 17.45 12.82 17 74864 3842 110510576
Hypoalbuminaemia 17.35 12.82 51 74830 28923 110485495
Retroperitoneal fibrosis 17.27 12.82 9 74872 751 110513667
Computerised tomogram abnormal 17.17 12.82 17 74864 3919 110510499
Balance disorder 17.16 12.82 33 74848 116527 110397891
Unresponsive to stimuli 17.15 12.82 11 74870 63779 110450639
Large intestine infection 17.05 12.82 18 74863 4474 110509944
Underdose 17.04 12.82 11 74870 63543 110450875
Liver function test increased 16.94 12.82 21 74860 88527 110425891
Cystitis 16.94 12.82 12 74869 66024 110448394
Myeloproliferative neoplasm 16.88 12.82 11 74870 1394 110513024
Enterocolitis haemorrhagic 16.77 12.82 14 74867 2590 110511828
Acute myeloid leukaemia recurrent 16.73 12.82 19 74862 5120 110509298
Lung adenocarcinoma 16.69 12.82 26 74855 9505 110504913
Pneumonia cytomegaloviral 16.63 12.82 22 74859 6932 110507486
Ear infection 16.62 12.82 11 74870 62721 110451697
Keratoacanthoma 16.58 12.82 11 74870 1437 110512981
Concomitant disease progression 16.51 12.82 16 74865 3594 110510824
Skin lesion 16.46 12.82 74 74807 51557 110462861
Pulmonary arterial hypertension 16.42 12.82 54 74827 32514 110481904
Bronchopulmonary aspergillosis 16.41 12.82 51 74830 29812 110484606
X-ray abnormal 16.36 12.82 3 74878 38114 110476304
Psychotic disorder 16.33 12.82 7 74874 50930 110463488
Syncope 16.30 12.82 76 74805 202460 110311958
Dysarthria 16.04 12.82 20 74861 84101 110430317
Spondylolysis 15.99 12.82 6 74875 227 110514191
Retinal vascular disorder 15.89 12.82 7 74874 402 110514016
Pityriasis rosea 15.84 12.82 6 74875 233 110514185
Genital discharge 15.81 12.82 4 74877 38 110514380
Mutagenic effect 15.60 12.82 3 74878 6 110514412
Adverse drug reaction 15.44 12.82 30 74851 105529 110408889
Haematology test abnormal 15.40 12.82 5 74876 122 110514296
Bone neoplasm 15.35 12.82 9 74872 946 110513472
Prescribed underdose 15.25 12.82 13 74868 65161 110449257
Hydrothorax 15.23 12.82 11 74870 1647 110512771
International normalised ratio increased 15.15 12.82 22 74859 86750 110427668
Oncologic complication 15.10 12.82 7 74874 453 110513965
Amyotrophic lateral sclerosis 15.06 12.82 12 74869 2079 110512339
Rash erythematous 15.06 12.82 101 74780 81731 110432687
Allogenic bone marrow transplantation therapy 15.04 12.82 4 74877 47 110514371
Toxic epidermal necrolysis 14.96 12.82 10 74871 56717 110457701
Thrombosis 14.95 12.82 32 74849 108630 110405788
Organising pneumonia 14.84 12.82 31 74850 14212 110500206
Cerebral infarction 14.84 12.82 72 74809 51766 110462652
Subclavian artery stenosis 14.82 12.82 6 74875 279 110514139
Right ventricular enlargement 14.79 12.82 9 74872 1012 110513406
Skin mass 14.77 12.82 25 74856 9791 110504627
Skin erosion 14.74 12.82 19 74862 5835 110508583
Monocyte morphology abnormal 14.74 12.82 3 74878 9 110514409
Acinetobacter sepsis 14.72 12.82 5 74876 141 110514277
Upper respiratory tract infection 14.70 12.82 43 74838 131285 110383133
Mental status changes 14.61 12.82 18 74863 76104 110438314
Cardiac arrest 14.59 12.82 76 74805 196677 110317741
Hepatic necrosis 14.57 12.82 25 74856 9897 110504521
Ocular discomfort 14.55 12.82 23 74858 8510 110505908
Karyotype analysis abnormal 14.53 12.82 4 74877 54 110514364
Biopsy bone marrow abnormal 14.52 12.82 7 74874 495 110513923
Oesophageal papilloma 14.50 12.82 3 74878 10 110514408
Maternal exposure during pregnancy 14.46 12.82 107 74774 254776 110259642
Blood fibrinogen decreased 14.43 12.82 13 74868 2662 110511756
Cystitis haemorrhagic 14.43 12.82 28 74853 12181 110502237
Bladder cancer 14.40 12.82 38 74843 20254 110494164
Lymphadenopathy 14.39 12.82 83 74798 63752 110450666
Osteoporosis 14.35 12.82 23 74858 87129 110427289
Aspergillus infection 14.31 12.82 44 74837 25572 110488846
Clear cell sarcoma of soft tissue 14.28 12.82 3 74878 11 110514407
Night sweats 14.18 12.82 45 74836 133938 110380480
Acoustic neuroma 14.18 12.82 6 74875 312 110514106
Oropharyngeal cancer 14.18 12.82 5 74876 158 110514260
Deep vein thrombosis 14.11 12.82 48 74833 139839 110374579
Effusion 14.10 12.82 13 74868 2744 110511674
Aspartate aminotransferase increased 14.09 12.82 168 74713 159768 110354650
Breast oedema 14.08 12.82 4 74877 61 110514357
Capillary leak syndrome 14.07 12.82 17 74864 4891 110509527
Intentional self-injury 13.96 12.82 4 74877 37425 110476993
Influenza like illness 13.94 12.82 24 74857 88388 110426030
Lactic acidosis 13.91 12.82 26 74855 92785 110421633
Vitreous adhesions 13.90 12.82 4 74877 64 110514354
Palatal disorder 13.90 12.82 7 74874 544 110513874
Haemangioma 13.86 12.82 13 74868 2803 110511615
Eczema asteatotic 13.86 12.82 8 74873 816 110513602
Tyrosine kinase mutation 13.85 12.82 4 74877 65 110514353
Colon operation 13.80 12.82 7 74874 552 110513866
Obstructive airways disorder 13.78 12.82 7 74874 46142 110468276
Gastrointestinal haemorrhage 13.77 12.82 172 74709 165346 110349072
Polyhydramnios 13.73 12.82 11 74870 1922 110512496
Paraesthesia oral 13.72 12.82 3 74878 33668 110480750
Blood pressure systolic inspiratory decreased 13.70 12.82 3 74878 14 110514404
Oligoasthenozoospermia 13.70 12.82 3 74878 14 110514404
Aggression 13.62 12.82 12 74869 59198 110455220
Throat tightness 13.61 12.82 3 74878 33486 110480932
Gastric haemorrhage 13.61 12.82 32 74849 15883 110498535
Complex regional pain syndrome 13.60 12.82 12 74869 2393 110512025
Leukaemic infiltration extramedullary 13.59 12.82 6 74875 346 110514072
Drug level increased 13.46 12.82 66 74815 47653 110466765
Splenectomy 13.46 12.82 8 74873 862 110513556
Gastric neoplasm 13.45 12.82 6 74875 355 110514063
Pulmonary tuberculosis 13.39 12.82 23 74858 9116 110505302
Oesophagectomy 13.37 12.82 3 74878 16 110514402
Therapeutic response unexpected 13.36 12.82 41 74840 23802 110490616
Hepatic failure 13.35 12.82 86 74795 68653 110445765
Gamma-glutamyltransferase increased 13.35 12.82 79 74802 61230 110453188
Leukaemic infiltration 13.33 12.82 5 74876 189 110514229
Tunnel vision 13.32 12.82 11 74870 2004 110512414
Myoclonus 13.32 12.82 3 74878 32995 110481423
Subdural haematoma evacuation 13.17 12.82 4 74877 78 110514340
Diabetic ketoacidosis 13.14 12.82 6 74875 42052 110472366
Skin atrophy 13.05 12.82 19 74862 6545 110507873
Hepatitis toxic 13.04 12.82 18 74863 5903 110508515
Melanosis 13.02 12.82 4 74877 81 110514337
Nightmare 13.01 12.82 5 74876 38858 110475560
B-cell small lymphocytic lymphoma 13.01 12.82 5 74876 202 110514216
Subdural haematoma 12.96 12.82 54 74827 36400 110478018
Lung diffusion test decreased 12.96 12.82 10 74871 1655 110512763
Scrotal oedema 12.87 12.82 10 74871 1671 110512747
Subcutaneous emphysema 12.86 12.82 12 74869 2572 110511846
Loss of consciousness 12.84 12.82 79 74802 196227 110318191

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EA01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
BCR-ABL tyrosine kinase inhibitors
FDA MoA N0000020009 Bcr-Abl Tyrosine Kinase Inhibitors
MeSH PA D000092004 Tyrosine Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33231 antitubercular agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:38068 antimalarial
CHEBI has role CHEBI:38637 tyrosine kinase inhibitor
CHEBI has role CHEBI:62868 hepatoprotective agent
CHEBI has role CHEBI:68495 apoptosis inducer

Related Drugs by ATC class:

L01EA BCR-ABL tyrosine kinase inhibitors 5 drugs
asciminibbosutinibdasatinibnilotinibponatinib

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Dermatofibrosarcoma protuberans indication 276799004
Systemic mast cell disease indication 397016004 DOID:349
Blastic phase chronic myeloid leukemia indication 413656006
Chronic eosinophilic leukemia indication 413836008
Chronic phase chronic myeloid leukemia indication 413847001
Gastrointestinal stromal tumor indication 420120006 DOID:9253
Idiopathic hypereosinophilic syndrome indication 423294001
Philadelphia chromosome-positive acute lymphoblastic leukemia indication 425688002
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia indication 449108003
Myelodysplastic/myeloproliferative diseases with re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR) indication 738527001
Chronic Myelocytic Leukemia Accelerated Phase indication
Heart valve disorder contraindication 368009 DOID:4079
Cerebral edema contraindication 2032001
Hypophosphatemia contraindication 4996001
Congenital heart disease contraindication 13213009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Pulmonary edema contraindication 19242006 DOID:11396
Hypertensive disorder contraindication 38341003 DOID:10763
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Myocarditis contraindication 50920009 DOID:820
Gastrointestinal perforation contraindication 51875005
Hepatic failure contraindication 59927004
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Left heart failure contraindication 85232009
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Bleeding contraindication 131148009
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Pericardial effusion contraindication 373945007 DOID:118
Purpuric disorder contraindication 387778001
Ascites contraindication 389026000
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Pleural Effusions contraindication
Chronic Heart Failure Following Myocardial Infarction contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.96 acidic
pKa2 8.49 Basic
pKa3 4.34 Basic
pKa4 3.73 Basic
pKa5 2.2 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 7.85 CHEMBL CHEMBL
Tyrosine-protein kinase ABL1 Kinase INHIBITOR Kd 8.96 CHEMBL CHEMBL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 7.89 CHEMBL CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 6.27 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.71 DRUG MATRIX
Carbonic anhydrase 2 Enzyme Ki 7.52 CHEMBL
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK
ATP-binding cassette sub-family G member 2 Transporter IC50 5.47 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 7.50 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 5.34 CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme IC50 6.40 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.12 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 6.01 CHEMBL
Epidermal growth factor receptor Kinase Kd 5.12 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 4.69 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 4.77 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Ki 4.51 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 7.40 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.51 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase Kd 5.77 CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 5.48 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 5.20 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 4.59 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.96 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 7.51 CHEMBL
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 10.22 CHEMBL
Insulin receptor Kinase AGONIST Ki 5 PDSP
Thromboxane-A synthase Enzyme IC50 6.70 DRUG MATRIX
Mitogen-activated protein kinase 8 Kinase Kd 5.49 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 6.28 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 6.41 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.51 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Ki 5 PDSP
Tyrosine-protein kinase SYK Kinase IC50 5.30 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 5.85 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.05 CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase Ki 5 PDSP
Carbonic anhydrase 14 Enzyme Ki 6.33 CHEMBL
Fibroblast growth factor receptor 1 Kinase Ki 5 PDSP
Serine/threonine-protein kinase PLK4 Kinase Kd 5.11 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 8.22 CHEMBL
Fibroblast growth factor receptor 2 Kinase Ki 5 PDSP
Serine/threonine-protein kinase 17A Kinase Kd 5.55 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 5.62 CHEMBL
Mitogen-activated protein kinase 14 Kinase IC50 4.86 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 5.82 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 5.35 CHEMBL
Cyclin-G-associated kinase Kinase Kd 6 CHEMBL
Ephrin type-B receptor 1 Kinase Ki 5 PDSP
Dual specificity protein kinase CLK4 Kinase Kd 5.68 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.28 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 9.15 CHEMBL
Ephrin type-B receptor 4 Kinase Ki 5 PDSP
Lysine--tRNA ligase Enzyme Ki 5.30 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 5.06 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 5.59 CHEMBL
Casein kinase II subunit alpha' Kinase Kd 5.42 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 5.72 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 5.37 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 7.82 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 6.28 CHEMBL
Cyclin-dependent kinase 19 Kinase Kd 5.26 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 6.02 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 5.92 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma Kinase Kd 6.42 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 5.38 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 7.40 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 6.46 CHEMBL
Solute carrier family 22 member 3 Transporter IC50 4.59 CHEMBL
Platelet-derived growth factor receptor Kinase IC50 7.30 CHEMBL
Tyrosine-protein kinase ABL Kinase IC50 7.40 CHEMBL
Bcr/Abl fusion protein Kinase Ki 7.85 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 6.96 CHEMBL
ATP-dependent RNA helicase DDX3X Enzyme Kd 6.36 CHEMBL
Multidrug resistance protein 1 Transporter IC50 5.14 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.13 DRUG MATRIX
Carbonic anhydrase 13 Enzyme Ki 5.13 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.11 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase IC50 5.56 CHEMBL
Tyrosine-protein kinase ABL1 Kinase IC50 7.97 CHEMBL
Platelet-derived growth factor receptor beta Kinase IC50 7.30 CHEMBL
Platelet-derived growth factor receptor beta Kinase IC50 6.79 CHEMBL

External reference:

IDSource
4021257 VUID
N0000148698 NUI
D01441 KEGG_DRUG
220127-57-1 SECONDARY_CAS_RN
4021257 VANDF
4021258 VANDF
C0939537 UMLSCUI
CHEBI:45783 CHEBI
STI PDB_CHEM_ID
CHEMBL941 ChEMBL_ID
CHEMBL1642 ChEMBL_ID
D000068877 MESH_DESCRIPTOR_UI
DB00619 DRUGBANK_ID
5687 IUPHAR_LIGAND_ID
8031 INN_ID
BKJ8M8G5HI UNII
5291 PUBCHEM_CID
282386 RXNORM
16030 MMSL
238904 MMSL
41395 MMSL
d04758 MMSL
009151 NDDF
009152 NDDF
129558005 SNOMEDCT_US
391634008 SNOMEDCT_US
414460008 SNOMEDCT_US
BKJ8M8G5HI INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0401 TABLET 100 mg ORAL NDA 31 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0649 TABLET 400 mg ORAL NDA 31 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-1490 TABLET 400 mg ORAL NDA 31 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7629 TABLET, FILM COATED 100 mg ORAL ANDA 27 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7630 TABLET, FILM COATED 400 mg ORAL ANDA 27 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2245 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2246 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
imatinib mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0832-0532 TABLET 100 mg ORAL ANDA 31 sections
imatinib mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0832-0533 TABLET 400 mg ORAL ANDA 31 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6621 TABLET, FILM COATED 400 mg ORAL ANDA 25 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6901 TABLET, FILM COATED 100 mg ORAL ANDA 25 sections
IMATINIB MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 31722-296 TABLET, FILM COATED 100 mg ORAL ANDA 27 sections
IMATINIB MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 31722-297 TABLET, FILM COATED 400 mg ORAL ANDA 27 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 42292-043 TABLET, FILM COATED 100 mg ORAL ANDA 30 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 42292-044 TABLET, FILM COATED 400 mg ORAL ANDA 30 sections
Imatinib HUMAN PRESCRIPTION DRUG LABEL 1 43598-344 TABLET 100 mg ORAL ANDA 25 sections
Imatinib HUMAN PRESCRIPTION DRUG LABEL 1 43598-344 TABLET 100 mg ORAL ANDA 25 sections
Imatinib HUMAN PRESCRIPTION DRUG LABEL 1 43598-345 TABLET 400 mg ORAL ANDA 25 sections
Imatinib HUMAN PRESCRIPTION DRUG LABEL 1 43598-345 TABLET 400 mg ORAL ANDA 25 sections
imatinib mesylate HUMAN PRESCRIPTION DRUG LABEL 1 47335-472 TABLET, FILM COATED 100 mg ORAL ANDA 29 sections
imatinib mesylate HUMAN PRESCRIPTION DRUG LABEL 1 47335-475 TABLET, FILM COATED 400 mg ORAL ANDA 29 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 48433-049 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 48433-050 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 51407-269 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 51407-270 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Imatinib Mesylate Human Prescription Drug Label 1 59651-240 TABLET, FILM COATED 100 mg ORAL ANDA 27 sections
Imatinib Mesylate Human Prescription Drug Label 1 59651-241 TABLET, FILM COATED 400 mg ORAL ANDA 27 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60505-2900 TABLET, FILM COATED 100 mg ORAL ANDA 25 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60505-2901 TABLET, FILM COATED 400 mg ORAL ANDA 25 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60687-882 TABLET, FILM COATED 100 mg ORAL ANDA 27 sections